Login to Your Account

Earnings Roundup

Incyte Earnings Beat Estimates; Jakafi Slowly Gaining Traction

By Catherine Shaffer
Staff Writer

Wednesday, August 8, 2012

Incyte Corp.'s launch of Jakafi (ruxolitinib) for myelofibrosis continues to gather momentum as physicians gradually expand its use to less severely ill patients. The Wilmington, Del.-based company reported Jakafi sales of $31.9 million for the second quarter of 2012, and $53.1 million for the first six months of the year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription